About This Trial
Bispecific antibody redirecting T-cells to BCMA-expressing myeloma cells.
Primary Endpoints
- Overall survival
- Complete response rate
Latest Update
February 2026
Phase 2 showed 63% overall response rate. Registrational Phase 3 fully enrolled ahead of schedule.